SIN-1 has no direct myocardial anti-ischemic action.
Anti-ischemic drugs may develop their cardiac activity via peripheral (reduction in preload and/or afterload) or cardiac (coronary vasculature, myocardial cell metabolism) effects. The aim of the study was to investigate whether SIN-1, the active metabolite of molsidomine, develops a direct myocardial anti-ischemic property. Three groups of seven patients each were treated with 0.4 mg SIN-1 administered via either the intracoronary (IC) or intravenous (IV) route, or with placebo in a double-blind randomized investigation. SIN-1 had no influence on either the ischemic parameters in the surface electrocardiogram (ECG) or the intracoronary ECG. There was also no change in peripheral or central hemodynamics or in the severity of angina following this low IC or IV dosage. There is no evidence of a direct myocardial anti-ischemic response of SIN-1. The well known anti-ischemic activity of SIN-1 or molsidomine has to be attributed to the proven peripheral and cardiac vascular responses.
Kober
G
G
Clinic Nordrhein, Bad Nauheim, Germany.
Bender
M
M
Vallbracht
C
C
Sievert
H
H
Klepzig
H
H
D015906:Angioplasty, Balloon, Coronary; D003326:Coronary Circulation / Q000187:drug effects; D003327:Coronary Disease / Q000628:therapy; D004311:Double-Blind Method; D004562:Electrocardiography; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008981:Molsidomine / Q000031:analogs & derivatives* / Q000494:pharmacology; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000503:physiopathology; D014665:Vasodilator Agents / Q000494:pharmacology*
D014665:Vasodilator Agents; C002385:linsidomine; D008981:Molsidomine